Firategrast - CAS# 402567-16-2 Size:Solid 10 mg Smiles: CN(C)CC1=C2C=C3CN4C(=CC5=C(COC(=O)[C@]5(O)CC)C4=O)C3=NC2=CC=C1O

Smiles: CN(C)CC1=C2C=C3CN4C(=CC5=C(COC(=O)[C@]5(O)CC)C4=O)C3=NC2=CC=C1O

23'-tetramethyl-5

1-[4-(2-methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol

Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis

PubMed PMID: 25569515

Firategrast - CAS# 402567-16-2 Size:Solid 10 mg Smiles: CN(C)CC1=C2C=C3CN4C(=CC5=C(COC(=O)[C@]5(O)CC)C4=O)C3=NC2=CC=C1OFirategrast, also known as SB 683699 or T 0047, is an orally bioavailable alpha4 beta1 alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS). This could decrease multiple sclerosis (MS) activity, but may compromise CNS immune surveillance. The integrins are a sort of transmembrane receptors that modulate the signal transduction from ECM to the cell. They are associated with a lot of